Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The only material change disclosed is a transaction involving Mr. S M Bicknell, who acquired a beneficial interest in 13 Ordinary shares. This acquisition resulted from the re-investment of dividends under a Personal Equity Plan on July 6, 2010, at a price of £11.00 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a compliance notification made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 6, 2010
- Individual: Mr. S M Bicknell
- Shares Acquired: 13 Ordinary shares
- Acquisition Price: £11.00 per share
- Method: Dividend re-investment via Personal Equity Plan
- Notification Date: July 7, 2010